The incidence of secondary outcomes was significantly lower in the rosuvastatin group compared with control group ( @ % vs. @ % , P = @ ) in the overall cohort , but it was similar between the patients with MCV ( @ % vs. @ % , P = @ ) or HCV ( @ % vs. @ % , P = @ ) .